

| | | | |
|-------------------------------|----------------------------|---------------------|--|
| Notice of Allowability | Application No. | Applicant(s) | |
| | 09/393,795 | GRAY ET AL. | |
| | Examiner | Art Unit | |
| | Gerald G. Leffers Jr., PhD | 1636 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the RCE filed 4/1/2005.
2. ☒ The allowed claim(s) is/are 1-3,5,7-10,12-14,16-18,20,22-25 and 27-29.
3. ☒ The drawings filed on 3/17/04 & 9/10/99 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|--|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413), Paper No./Mail Date _____. |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____ | 7. <input type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____. |

REASONS FOR ALLOWANCE***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114.

Applicants' submission filed on 4/1/2005 has been entered.

The papers submitted on 4/1/2005 comprise a pair of signed copies of a declaration under 37 CFR 1.132 from Dr. John T. Gray and Dr. Jeng-Shin Lee concerning data generated using one of the *gagpol* expression vectors taught in the instant application (i.e. pHDMHgpm2). The new declaration presents the same data originally presented in the declaration submitted by Dr. Gray in the papers filed on 3/17/2003. In addition, new technical matter is presented. For example, transfected cell clones that produced high levels of p24 were further analyzed for expression of HIV reverse transcriptase (RT), which is a processed product of HIV pol (e.g. page 4, 2nd paragraph of the declaration). The declaration states that in addition to expressing high levels of p24, a processed product of HIV *pol*, the chosen cell lines also express high levels of HIV RT (e.g. page 5, last paragraph). The new declaration also corrects an inadvertent error on the part of Dr. Gray in the old declaration where he indicated that the work done for the 3/17/2003 declaration was done in his lab or under his supervision. The new declaration, signed by both Dr. Gray and Dr. Jeng-Shin Lee, indicates the work was done in Dr. Lee's lab or under his supervision.

Art Unit: 1636

The following is an examiner's statement of reasons for allowance: the additional information presented in the declaration submitted on 4/1/2005, signed by both Dr. Gray and Dr. Jeng-Shin Lee, does not alter the conclusion that applicants were enabled for the packaging cells and methods recited in the allowed claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."


Conclusion

Claims 1-3, 5, 7-10, 12-14, 16-18, 20, 22-25 & 27-29 (now claims 1-22).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G. Leffers Jr., PhD whose telephone number is (571) 272-0772. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


GERRY LEFFERS
PRIMARY EXAMINER

Gerald G Leffers Jr., PhD
Primary Examiner
Art Unit 1636

ggl